Elanco Animal Health Incorporated - ELAN STOCK NEWS

Elanco celebrates its annual Global Day of Purpose (GDOP) with over 150 volunteer events worldwide. During October's Global Month of Purpose, employees contributed more than 11,000 volunteer hours through various initiatives. Notable activities include: The Warsaw team building animal enrichment items for the local zoo; 500 employees at Indianapolis HQ packing 100,000 meals for Rise Against Hunger; Taiwan team removing invasive plants; Japan conducting local cleanups; and Italy supporting charities and animal shelters.

The initiative has evolved from a single day to become a year-round program, with employees participating in activities ranging from river and park cleanups to animal shelter support and environmental conservation efforts, demonstrating Elanco's commitment to improving the lives of animals, people, and the environment.

Elanco Animal Health (NYSE: ELAN) has announced its management's participation in two upcoming investor conferences. Todd Young, executive vice president and CFO, will participate in:

- A fireside chat at the Evercore ISI 7th Annual HealthCONx on Tuesday, December 3, at 11:15 a.m. ET
- The Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, at 1:30 p.m. ET

Live audio webcasts will be accessible through Elanco's investor website under 'Events and Presentations,' with replays available for approximately 30 days.

Dr. Elise Kelly, a veterinarian at Elanco Animal Health, discovered the presence of potentially deadly Echinococcus tapeworms in wild animal feces in her Missouri backyard. This finding highlights a significant but often overlooked threat to both pets and humans. According to an Elanco survey, nearly half of dog owners are unaware that their pets face year-round intestinal worm risks, while 73% prefer preventive protection over reactive treatment. The company promotes Interceptor Plus, a monthly chew that protects dogs against five common types of worms, including heartworm disease, hookworm, roundworm, tapeworm, and whipworm infections.

The Schall Law Firm announces a class action lawsuit against Elanco Animal Health (NYSE:ELAN) for alleged violations of securities laws. The lawsuit covers investors who purchased securities between November 7, 2023 and June 26, 2024. The complaint alleges that Elanco made false and misleading statements about the safety of Zenrelia and overstated the timeline for launching Zenrelia and Credelio Quattro. Affected shareholders have until December 6, 2024 to join the lawsuit. The lawsuit claims investors suffered damages when the market learned the truth about these misrepresentations.

Elanco Animal Health (NYSE: ELAN) has acquired a contract manufacturing facility in Speke, UK, previously owned by TriRx Speke , which was under trading administration. The facility is important for producing farm animal product lines worth $160-180 million in annual revenue, primarily outside the U.S. The acquisition, completed for $25 million in cash, secures a critical component of Elanco's global supply chain. The company expects an adjusted EBITDA headwind of $25-35 million in 2025, mainly affecting gross profit.

Elanco Animal Health (NYSE: ELAN) has appointed Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma, currently Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences, brings extensive experience in biopharmaceutical development and manufacturing. She previously held leadership positions at Sana Biotechnology and Genentech/Roche. Dr. Ma was recognized as one of the 'Top 20 Women Leaders in Biopharma R&D' by Endpoints News in 2020 and is a Fellow of the American Institute for Medical and Biological Engineering. Her expertise will support Elanco's Innovation, Portfolio and Productivity strategy and development of next-generation pipeline products.

Elanco Animal Health (NYSE: ELAN) reported Q3 2024 revenue of $1,030 million, with 1% organic constant currency growth. The company posted reported net income of $364 million and adjusted net income of $66 million. Adjusted EBITDA was $163 million (15.8% of revenue), with reported EPS of $0.73 and adjusted EPS of $0.13.

The company recorded a pre-tax gain of $640 million from July 2024 aqua business divestiture and tightened its full-year 2024 guidance to revenue of $4,420-4,450 million. Notable achievements include U.S. FDA approvals for Zenrelia and Credelio Quattro. For 2025, Elanco expects mid-single-digit organic revenue growth, with adjusted EBITDA growth in low single digits.

At the recent Reuters Transform Food & Agriculture event, 200 industry leaders discussed key requirements for transforming the future of food. The focus areas included: supply chain integration, developing scalable and profitable innovations for farmers, and maintaining a growth mindset. Katie Cook, VP of Livestock Sustainability and U.S. Farm Animal Marketing, moderated a panel with representatives from various agricultural companies, discussing supply chain collaborations and innovations. A fireside chat with Jackie Klippenstein from Dairy Farmers of America addressed initiatives for reducing and measuring enteric methane emissions, particularly focusing on Scope 3 emissions reductions.

Rigrodsky Law, P.A. has announced an investigation into potential claims against the officers and directors of Elanco Animal Health Incorporated (NYSE:ELAN) on behalf of stockholders. The investigation concerns shareholders who purchased or acquired Elanco shares on or before November 7, 2023. Interested parties are encouraged to visit the law firm's website or contact Leah Wihtelin for more information about the investigation and their rights. This announcement suggests possible legal action related to Elanco's corporate governance or business practices, which could potentially impact shareholders.